Form 4 for KYNB KYNTRA BIO, INC.
Accepted 2022-12-15 00:00:00 ET · period of report 2022-12-08 · accession 0001209191-22-061483 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-12-15 | 2022-12-08 | KYNB | Graham Juan | CFO | S - Sale | $14.89 | -5,741 | 50.6K | -10% | -$85.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-08 | S | D | 478 | $15.47 | 50,150 | D | — | — | (F1) Shares sold pursuant to a 10b5-1 plan. |
| 2 | Common | Common Stock | 2022-12-08 | S | D | 5,263 | $14.84 | 50,628 | D | — | — | (F1) Shares sold pursuant to a 10b5-1 plan. (F2) These shares were sold in multiple transactions on the reported date with prices ranging from $14.38 to $15.355 resulting in a weighted average price of $14.84. Upon request, the reporting person will provide to the Commission staff or a security holder of the Issuer the number of shares sold and the sale price for each separate transaction. |